News & Updates

Show Multimedia Only

Increase in hs-cTnI rare during normal delivery

10 Sep 2026

Assessment of high-sensitivity cardiac troponin I (hs-cTnI) trajectories during the immediate peripartum period hint at delivery as a physiologic cardiovascular “stress test,” according to a study.

Increase in hs-cTnI rare during normal delivery

10 Sep 2026

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia

10 Sep 2026 by

In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia

10 Sep 2026

Early ECG monitoring does not prevent syncope recurrence, but may improve survival

09 Sep 2026 by

Immediate ambulatory electrocardiographic (ECG) monitoring initiated among patients with syncope in the emergency department (ED) falls short of preventing recurrent syncope over 1 year, according to the ASPIRED study presented at ESC Congress 2026.

Early ECG monitoring does not prevent syncope recurrence, but may improve survival

09 Sep 2026

Tailored therapy reduces antibiotic use in infective endocarditis

09 Sep 2026 by

A response-tailored strategy decreases antibiotic duration by 2 weeks compared with standard therapy in patients with left-sided infective endocarditis, without compromising their safety. This is the primary result of the POET-II study presented at ESC Congress 2026.

Tailored therapy reduces antibiotic use in infective endocarditis

09 Sep 2026

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

08 Sep 2026 by

Among nondiabetic patients with first-onset ST-elevation myocardial infarction (STEMI), stress hyperglycaemia is more likely to occur in older patients but is associated with the greatest risk of mortality in younger patients, according to local research.

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

08 Sep 2026

Sleep apnoea ups CVD risk in patients with cancer

06 Sep 2026 by

Obstructive sleep apnoea (OSA) contributes to an increased risk of cardiovascular disease (CVD) events for patients with cancer, and this risk increase persists regardless of obesity status and is more pronounced in women, according to a retrospective study.

Sleep apnoea ups CVD risk in patients with cancer

06 Sep 2026

CVD risk in lupus patients lower with anifrolumab vs belimumab

04 Sep 2026

In the treatment of patients with systemic lupus erythematosus, anifrolumab is associated with reduced cardiovascular disease (CVD) risk compared with belimumab, as shown in a retrospective study.

CVD risk in lupus patients lower with anifrolumab vs belimumab

04 Sep 2026

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026 by

In patients with serious mental illness (SMI), initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower risks of all-cause mortality and major adverse cardiovascular events (MACEs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors, a large study has shown.

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026

Original New Drug Application Approvals by US FDA (1-15 December 2025)

03 Sep 2026

New drug applications approved by US FDA as of 1-15 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 December 2025)

03 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

News & Updates

Showing Cardiology articles

Showing

Specialty:

Increase in hs-cTnI rare during normal delivery

Increase in hs-cTnI rare during normal delivery

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia

Early ECG monitoring does not prevent syncope recurrence, but may improve survival

Early ECG monitoring does not prevent syncope recurrence, but may improve survival

Tailored therapy reduces antibiotic use in infective endocarditis

Tailored therapy reduces antibiotic use in infective endocarditis

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

Sleep apnoea ups CVD risk in patients with cancer

Sleep apnoea ups CVD risk in patients with cancer

CVD risk in lupus patients lower with anifrolumab vs belimumab

CVD risk in lupus patients lower with anifrolumab vs belimumab

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

Original New Drug Application Approvals by US FDA (1-15 December 2025)

Original New Drug Application Approvals by US FDA (1-15 December 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)